4
Changes in Ownership
Atara Biotherapeutics, Inc. Filed Acc 0001140361-22-007765
EVP, Head of R&D sold 2,221 shares at $9.86 ($21,890)
- EVP, Head of R&D acquired 78,506 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Dupont Jakob EVP, Head of R&D | 2022-03-01 | Grant or award | +78,506 | 169,100 | D | ||
| Dupont Jakob EVP, Head of R&D | 2022-03-01 | Sale | −2,221 | $9.86 | $21,890 | 166,879 | D |
| Derivatives | |||||||
| Dupont Jakob EVP, Head of R&D | 2022-03-01 | Grant or award · Employee Stock Option (Right to Buy) | +147,573 | 147,573 | D | ||
| Open-market sales · 2,221 sh · avg $9.86 · $21,890 | |||||||
Loading xslF345X03/form4.xml…